Jae Man Lee

Dr. Jae Man Lee

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Immune Network
Verified
Journal Article
Open access
JJJae-Han Jeon
Jae-Han Jeon
CHChang-Won Hong
Chang-Won Hong
EKEun Young Kim
Eun Young Kim
JLJae Man Lee
Jae Man Lee
Jeon JH, et al. Immune Netw. 2020 Nov;20(6):e46. https://doi.org/10.4110/in.2020.20.e46

3 July 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
TKTae Yeon Kim
Tae Yeon Kim
ELEunju Leem
Eunju Leem
JLJae Man Lee
Jae Man Lee
Sang Ryong KimSang Ryong Kim
Sang Ryong Kim
Oxidative stress reflects an imbalance between the production of reactive oxygen species (ROS) and antioxidant defense systems, and it can be associated with the pathogenesis and progression of neurodegenerative diseases such as multiple sclerosis, stroke, and Parkinson’s disease (PD). The application of antioxidants, which can defend against oxidative stress, is able to detoxify the reactive intermediates and prevent neurodegeneration resulting from excessive ROS production. There are many reports showing that numerous flavonoids, a large group of natural phenolic compounds, can act as antioxidants and the application of flavonoids has beneficial effects in the adult brain. For instance, it is well known that the long-term consumption of the green tea-derived flavonoids catechin and epigallocatechin gallate (EGCG) can attenuate the onset of PD. Also, flavonoids such as ampelopsin and pinocembrin can inhibit mitochondrial dysfunction and neuronal death through the regulation of gene expression of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. Additionally, it is well established that many flavonoids exhibit anti-apoptosis and anti-inflammatory effects through cellular signaling pathways, such as those involving (ERK), glycogen synthase kinase-3β (GSK-3β), and (Akt), resulting in neuroprotection. In this review article, we have described the oxidative stress involved in PD and explained the therapeutic potential of flavonoids to protect the nigrostriatal DA system, which may be useful to prevent PD.

1 June 2020 in Journal of Hepatology
Verified
Journal Article
Open access
KPKatrin Panzitt
Katrin Panzitt
EJEmilian Jungwirth
Emilian Jungwirth
EKElisabeth Krones
Elisabeth Krones
JLJae Man Lee
Jae Man Lee
MPMarion Pollheimer
Marion Pollheimer
MWMartin Wagner
Martin Wagner
Cholestasis comprises a spectrum of liver diseases characterized by the accumulation of bile acids. Bile acids and activation of the farnesoid X receptor (FXR) can inhibit autophagy, a cellular self-digestion process necessary for cellular homeostasis and regeneration. In mice, autophagy appears to be impaired in cholestasis and induction of autophagy may reduce liver injury. Herein, we explored autophagy in human cholestasis in vivo and investigated the underlying molecular mechanisms in vitro. FXR chromatin immunoprecipitation-sequencing and qPCR were performed in combination with luciferase promoter studies to identify functional FXR binding targets in a human cholestatic liver sample. Autophagic processing appeared to be impaired in patients with cholestasis and in individuals treated with the FXR ligand obeticholic acid (OCA). In vitro, chenodeoxycholic acid and OCA inhibited autophagy at the level of autophagosome to lysosome fusion in an FXR-dependent manner. Rubicon, which inhibits autophago-lysosomal maturation, was identified as a direct FXR target that is induced in cholestasis and by FXR-agonistic bile acids. Genetic inhibition of Rubicon reversed the bile acid-induced impairment of autophagic flux. In contrast to OCA, ursodeoxycholic acid (UDCA), which is a non-FXR-agonistic bile acid, induced autophagolysosome formation independently of FXR, enhanced autophagic flux and was associated with reduced Rubicon levels. In models of human cholestasis, autophagic processing is impaired in an FXR-dependent manner, partly resulting from the induction of Rubicon. UDCA is a potent inducer of hepatic autophagy. Manipulating autophagy and Rubicon may represent a novel treatment concept for cholestatic liver diseases. Autophagy, a cellular self-cleansing process, is impaired in various forms of human cholestasis. Bile acids, which accumulate in cholestatic liver disease, induce Rubicon, a protein that inhibits proper execution of autophagy. Ursodeoxycholic acid, which is the first-line treatment option for many cholestatic liver diseases, induces hepatic autophagy along with reducing Rubicon.

1 January 2020 in The Korean Journal of Physiology & Pharmacology
Verified
Journal Article
Open access
PDF file
SSSanjeeb Shrestha
Sanjeeb Shrestha
JLJae Man Lee
Jae Man Lee
CHChang-Won Hong
Chang-Won Hong
Shrestha S, et al. Korean J Physiol Pharmacol. 2020 Jan;24(1):1-10. https://doi.org/10.4196/kjpp.2020.24.1.1

12 May 2007 in Journal of Proteome Research
Verified
Journal Article
Closed access
PZPingbo Zhang
Pingbo Zhang
YAYoichi Aso
Yoichi Aso
HJHiroyuki Jikuya
Hiroyuki Jikuya
TKTakahiro Kusakabe
Takahiro Kusakabe
JLJae Man Lee
Jae Man Lee
HFHiroshi Fujii
Hiroshi Fujii

1 January 2016 in Annals of Pediatric Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JLJae Man Lee
Jae Man Lee
Nuclear receptors are in general ligand-dependent transcription factors that control a variety of mammalian physiologies including development, differentiation, proliferation, and homeostasis. Recent studies have found that two nutrient-sensing nuclear receptors, peroxisome proliferator-activated receptor α and farnesoid x receptor, responding to fasting or feeding state, respectively are able to regulate autophagy, an evolutionarily conserved catabolic process involved in lysosomal degradation. In this review, we discuss the role of these nutrient-sensing nuclear receptors in an aspect of transcriptional regulation of autophagy, and how these nuclear receptor-driven transcriptional programs integrate lipophagy, a lipid autophagy with fatty acid oxidation to coordinate hepatic lipid metabolism in the fasted state of the liver.